Skip to main content
OpenTrials
Completed

NCT Number: NCT04950660

Oral Caffeine Use for Pain Management in AIS Patients After Spinal Fusion

Prospective, randomized control trial To determine if oral caffeine decreases the frequency of opioid demand in children with adolescent idiopathic scoliosis after their spinal fusion surgery To compare pain scale ratings, number of requests for diazepam, average heart rate, average blood pressure, sex, age, ethnicity, post-op day of discharge, operative time, estimated intraoperative blood loss, remittance post-surgery, length of hospital stay, and segments fused during spinal fusion surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Children'S Mercy Hospitals & Clinic

Kansas City, Missouri, 64114, United States

About this study

Because these receptors are so important for modifying pain and inflammation, caffeine has been added as an adjuvant to common analgesics, such as paracetamol, ibuprofen, and aspirin in the belief that it will enhance their analgesic efficacy. Most studies used paracetamol or ibuprofen with 100 mg to 130 mg caffeine, and the most common pain conditions studied were postoperative dental pain, postpartum pain, and headache. There was a small but statistically significant benefit with caffeine used at doses of 100 mg or more, which was not dependent on the pain condition or type of analgesic. Additionally, trials have shown superior efficacy of adding caffeine to ibuprofen instead of administering ibuprofen alone for treating acute pain, reflecting that caffeine is an effective analgesic adjuvant. The addition of caffeine (≥ 100 mg) to a standard dose of commonly used analgesics provides a small but important increase in the proportion of participants who experience a good level of pain relief.

Finally, the beneficial effects of caffeine on aerobic activity and resistance training performance are well documented. Studies have shown that caffeine ingestion resulted in significantly lower levels of soreness compared with placebo (p ≤ 0.05). A further beneficial effect of sustained caffeine ingestion in the days after the exercise bout is an attenuation of delayed onset muscle soreness. Orthopaedic surgery also causes muscle injury, and patients might benefit from caffeine's effect on lowering muscle soreness. Acute caffeine administration also has been shown to demonstrate increases in alertness, contentment, motivation to work, talkativeness, and energy. It also decreases muscle twitches. All of these effects would be beneficial in the post-operative period, especially for Adolescence Idiopathic Scoliosis (AIS) patients undergoing spinal fusion surgery in the orthopaedic department at Children's Mercy Hospital.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • must meet criteria for surgical correction of scoliosis
  • must be able to swallow pills
  • must have English as a primary language
  • must possess mental capacity to understand purpose of the study
  • patient must carry diagnosis of adolescent idiopathic scoliosis
  • surgery must be performed via posterior approach
  • operation performed by either Dr. John T. Anderson, Dr. Richard M. Schwend, Dr. Aaron Shaw, Dr. Michael Benvenuti
  • post-surgical AIS patients from June 2019-June 2024
  • the patient must be between the ages of 12 and 17 years old
  • the patient and one of their biological parents or guardian(s) must give consent for patient to be included in this study
  • Negative Suicide screen

Exclusion criteria

  • obesity, as defined by a BMI at or above the 95th percentile
  • weight below 40 kg
  • any orthopedic diagnosis other than AIS
  • revision spine surgery
  • anterior or combined approach
  • admission to PICU post-op
  • use of Oxycodone post-op
  • allergies to ibuprofen, caffeine, codeine, or diazepam
  • history of renal disease
  • history of a coagulation disorder
  • history of cardiac dysrhythmia or open heart surgery
  • history of Chronic Pain Syndrome or Complex Regional Pain Syndrome
  • current use of oral central nervous system stimulant (e.g. methylphenidate)
  • Positive Suicide screen

The following populations will be excluded:

  • Children over the age of 18, or turning 18 during time of surgical treatment
  • Children or parents unable to consent
  • Individuals with cognitive delays
  • Pregnant females
  • Prisoners
  • Wards of the state

Treatment and study plan

Caffeine Tablet

Drug

Caffeine is approved by the FDA as a stimulant. A stimulant approved by the United States Food and Drug Administration (FDA) for the treatment to increase mental alertness and in combination with painkiller to treat migraine headaches. It is approved in the form of pill or tablet.

Other names: Caffeine

Placebo

Drug

Placebo, empty opaque dark blue blank capsule, taken twice daily. This will be an adjuvant to their standard pain control.

Other names: Blank

Primary outcomes

  1. Total Post Operative Oral Morphine Milligram Equivalents (MME)/Kilogram (Kg) for Hospital Stay

    Time frame: For hospital stay up to 7 days

    Total Post Operative Oral Morphine milligram equivalents (MME)/kilogram (Kg) for Hospital Stay

Secondary outcomes

  1. Mean Daily Verbal Analog Scale (VAS)

    Time frame: For hospital stay up to 7 days

    Utilizing Verbal Analog Scale 0-10, 0 being no pain and 10 being severe pain

  2. Average Heart Rate During Hospital Stay

    Time frame: For hospital stay up to 7 days

    Documented heart rates which are then averaged over 24 hours

  3. Average Systolic Blood Pressure During Hospital Stay

    Time frame: For hospital stay up to 7 days

    Documented systolic blood pressures which are then averaged over 24 hours

Sponsors and collaborators

Lead sponsor

Children's Mercy Hospital Kansas City

Other

Registry information

Official study title

Oral Caffeine Decreases the Frequency of Opioid Demand in AIS Patients After Spinal Fusion

Important dates

Study start
2019
Primary completion
2024
Study completion
2024
First posted
Jul 6, 2021
Registry last updated
Feb 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.